Perform Another (Advanced) Search

1.  Study Posting (77) Trial #156844, Prostate Cancer, New Hyde Park, NY
...Information A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone to placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate ...
View Page

2.  Study Posting (4519) Trial #125716, Myelodysplastic Syndromes (MDS), Cádiz, Spain
...MDS), Cádiz, Spain Trial Information A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. Status: Completed Protocol Number: ML20559 Sponsor: Hoffmann ...
...Title: An open label study of the effects of a combination of NeoRecormon, CellCept and prednisone on hematological parameters and cytogenesis in patients with low or intermediate risk myelodysplastic syndromes.? Brief ...
View Page

3.  Study Posting (4519) Trial #122633, Myelodysplastic Syndromes (MDS), Barcelona, Spain
...MDS), Barcelona, Spain Trial Information A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. Status: Completed Protocol Number: ML20559 Sponsor: Hoffmann ...
...Title: An open label study of the effects of a combination of NeoRecormon, CellCept and prednisone on hematological parameters and cytogenesis in patients with low or intermediate risk myelodysplastic syndromes.? Brief ...
View Page

4.  Study Posting (4519) Trial #123446, Myelodysplastic Syndromes (MDS), Barakaldo, Spain
...MDS), Barakaldo, Spain Trial Information A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. Status: Completed Protocol Number: ML20559 Sponsor: Hoffmann ...
...Title: An open label study of the effects of a combination of NeoRecormon, CellCept and prednisone on hematological parameters and cytogenesis in patients with low or intermediate risk myelodysplastic syndromes.? Brief ...
View Page

5.  Study Posting (4519) Trial #124373, Myelodysplastic Syndromes (MDS), Palma de Mallorca, Spain
...de Mallorca, Spain Trial Information A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. Status: Completed Protocol Number: ML20559 Sponsor: Hoffmann ...
...Title: An open label study of the effects of a combination of NeoRecormon, CellCept and prednisone on hematological parameters and cytogenesis in patients with low or intermediate risk myelodysplastic syndromes.? Brief ...
View Page

6.  Study Posting (2348) Trial #39500, Prostate Cancer, New York, NY
...Prostate Cancer, New York, NY Sponsor: CALGB" /> Trial Information Docetaxel and Estramustine versus Mitoxantrone and Prednisone for Advanced Hormone Refractory Prostate Cancer, Phase III Sponsor: CALGB This research study will compare two active chemotherapy regimens(docetaxel and estramustine versus mitoxantrone and prednisone) on advanced prostate cancer which no longer responds to hormone therapy to see the benefit ...
View Page

7.  CenterWatch: Clinical Trials in Category (95) Lymphomas
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma Arizona ...
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma Duarte ...
View Page

8.  Study Posting (1918) Trial #85467, Adenocarcinoma, Savannah, GA
...Information CALGB 90401: A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Hormone Refractory Prostate Cancer Condition: Adenocarcinoma of the ...
...Eligible patients will be randomized to receive either Decadron (oral), Docetaxel (IV), Placebo(IV) and Prednisone(oral) OR Decadron(oral), Docetaxel(IV), Bevacizumab(IV) and Prednisone(oral) every 3 weeks until ...
View Page

9.  Study Posting (5304) Trial #151180, Lymphomas, Marshfield, WI
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

10.  Study Posting (5304) Trial #151188, Lymphomas, Huntington, WV
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

11.  Study Posting (5304) Trial #151193, Lymphomas, Ogden, UT
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

12.  Study Posting (5304) Trial #151197, Lymphomas, Richardson, TX
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

13.  Study Posting (5304) Trial #151201, Lymphomas, Pittsburgh, PA
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma[DISABLED ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

14.  Study Posting (5304) Trial #151178, Lymphomas, Pittsburgh, PA
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

15.  Study Posting (5304) Trial #151179, Lymphomas, Philadelphia, PA
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

16.  Study Posting (5304) Trial #151174, Lymphomas, Valhalla, NY
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

17.  Study Posting (5304) Trial #151191, Lymphomas, Lebanon, NH
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

18.  Study Posting (5304) Trial #151200, Lymphomas, Lincoln, NE
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

19.  Study Posting (5304) Trial #151181, Lymphomas, Hutchinson, KS
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page

20.  Study Posting (5304) Trial #151182, Lymphomas, Skokie, IL
...Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma In ...
...to determine whether VELCADE in combination with either rituximab (R), cyclophosphamide (C), doxorubicin (A), and prednisone (P) (ie, VELCADE-R-CAP) or rituximab, cyclophosphamide, and prednisone (ie, VELCADE-R-CP) provides ...
View Page